相似文献
1
Co-infections: testing macrolides for added benefit in patients with COVID-19.
Lancet Microbe. 2020 Dec;1(8):e313. doi: 10.1016/S2666-5247(20)30170-1. Epub 2020 Nov 2.
2
Macrolides for patients with COVID-19 and concurrent pertussis infection.
Diagn Microbiol Infect Dis. 2021 Feb;99(2):115245. doi: 10.1016/j.diagmicrobio.2020.115245. Epub 2020 Oct 16.
3
Understanding the role of bacterial and fungal infection in COVID-19.
Clin Microbiol Infect. 2021 Jan;27(1):9-11. doi: 10.1016/j.cmi.2020.09.025. Epub 2020 Oct 9.
4
Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530.
5
Bacterial co-infections with SARS-CoV-2.
IUBMB Life. 2020 Oct;72(10):2097-2111. doi: 10.1002/iub.2356. Epub 2020 Aug 8.
6
Underestimation of co-infections in COVID-19 due to non-discriminatory use of antibiotics.
J Infect. 2020 Sep;81(3):e29-e30. doi: 10.1016/j.jinf.2020.06.077. Epub 2020 Jul 3.
7
Repurposing of antibiotics for clinical management of COVID-19: a narrative review.
Ann Clin Microbiol Antimicrob. 2021 May 21;20(1):37. doi: 10.1186/s12941-021-00444-9.
8
Antibiotic use in patients with Coronavirus disease 2019 (COVID-19): outcomes and associated factors.
Acta Clin Belg. 2022 Jun;77(3):579-587. doi: 10.1080/17843286.2021.1916300. Epub 2021 Apr 26.
9
Co-infection of influenza B virus and SARS-CoV-2: A case report from Taiwan.
J Microbiol Immunol Infect. 2021 Apr;54(2):336-338. doi: 10.1016/j.jmii.2020.06.011. Epub 2020 Jun 30.
10
Could the COVID-19 pandemic aggravate antimicrobial resistance?
Am J Infect Control. 2020 Sep;48(9):1129-1130. doi: 10.1016/j.ajic.2020.06.192. Epub 2020 Jun 27.
引用本文的文献
1
Precision spatiotemporal analysis of large-scale compound-protein interactions through molecular dynamics simulation.
PNAS Nexus. 2025 Mar 22;4(3):pgaf094. doi: 10.1093/pnasnexus/pgaf094. eCollection 2025 Mar.
2
Genomic analysis of isolates from bacteremia reveals genetic features associated with the COVID-19 pandemic.
iScience. 2024 Jun 28;27(8):110402. doi: 10.1016/j.isci.2024.110402. eCollection 2024 Aug 16.
3
The Antibiotic Kitasamycin-A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?
Pharmaceutics. 2023 Jan 18;15(2):329. doi: 10.3390/pharmaceutics15020329.
4
COVID-19 and the Importance of Being Prepared: A Multidisciplinary Strategy for the Discovery of Antivirals to Combat Pandemics.
Biomedicines. 2022 Jun 7;10(6):1342. doi: 10.3390/biomedicines10061342.
5
The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling.
J Mol Graph Model. 2022 Jul;114:108193. doi: 10.1016/j.jmgm.2022.108193. Epub 2022 Apr 18.
6
Pathogenesis and Management of COVID-19.
J Xenobiot. 2021 May 21;11(2):77-93. doi: 10.3390/jox11020006.
7
COVID-19 drug practices risk antimicrobial resistance evolution.
Lancet Microbe. 2021 Apr;2(4):e135-e136. doi: 10.1016/S2666-5247(21)00039-2. Epub 2021 Feb 24.
本文引用的文献
1
Co-infections: potentially lethal and unexplored in COVID-19.
Lancet Microbe. 2020 May;1(1):e11. doi: 10.1016/S2666-5247(20)30009-4. Epub 2020 Apr 24.
2
Azithromycin for COVID-19: More Than Just an Antimicrobial?
Clin Drug Investig. 2020 Aug;40(8):683-686. doi: 10.1007/s40261-020-00933-3.
3
The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).
Ageing Res Rev. 2020 Sep;62:101091. doi: 10.1016/j.arr.2020.101091. Epub 2020 May 24.
4
The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms.
Front Immunol. 2018 Mar 13;9:302. doi: 10.3389/fimmu.2018.00302. eCollection 2018.
5
Azithromycin: mechanisms of action and their relevance for clinical applications.
Pharmacol Ther. 2014 Aug;143(2):225-45. doi: 10.1016/j.pharmthera.2014.03.003. Epub 2014 Mar 11.
Zotero 插件